title: MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer.
abstract: The p53 gene and MDM2 gene play critical roles in cell cycle arrest and apoptosis together. Here, we evaluated the associations of prostate cancer risk and survival with the joint effects of mdm2 and p53 polymorphisms. Totally 1,193 cases and 1,310 age frequency-matched controls were included in the study. Prostate cancer patients were followed to determine the intervals of overall survival and disease-free survival. The Pro72Arg Pro allele (homozygous and heterozygous) were significantly associated with prostate cancer risk with an odds ratio (OR) of 0.77 [95% confidence interval(CI), 0.64-0.93]. SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro alleles carriers (OR=0.79, 95% CI, 0.64-0.98). In addition, compared with the Pro72Arg Pro alleles and SNP309 G homozygous, patients carrying both SNP309 T alleles and Pro72Arg Arg homozygous had more favorable disease-free survival (hazard ratio [HR] = 0.59, 95% CI, 0.38-0.93). Our results indicated that SNP309 and Pro72Arg polymorphisms may jointly contribute to the etiology and prognosis of prostate cancer.
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xue
authors.affiliation: The Helmholtz Sino-German Research Laboratory for Cancer, Department of Pathology, Tangdu Hospital, The Fourth Military Medical University, Xian, China.
authors.forename: Xiujuan
authors.initials: X
authors.lastname: Han
authors.affiliation: Department of Pathology, School of Basic Medicine, Fourth Military Medical University, Xian, Shaanxi, China.
authors.forename: Rongrong
authors.initials: R
authors.lastname: Liu
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Ziming
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Hecheng
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Zhenlong
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xian, China.
authors.forename: Tie
authors.initials: T
authors.lastname: Chong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D065840:Protective Factors; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
keywords: MDM2 gene; p53 gene; prostate cancer; risk; survival